KOF,Coca-Cola FEMSA, SAB de CV | Consumer Staples

KOF

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Coca-Cola FEMSA, SAB de CVKOF

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Coca-Cola FEMSA, S.A.B. de C.V., a franchise bottler, produces, markets, sells, and distributes Coca-Cola trademark beverages.

The company offers sparkling beverages, including colas and flavored sparkling beverages; and waters and other beverages, such as juice drinks, coffee, teas, milk, value-added dairy products, sports and energy drinks, alcoholic beverages, and plant-based drinks.

It provides a portfolio of products through retail outlets, wholesale supermarkets, retailers, points-of-sale outlets, and home delivery.

In addition, the company distributes and sells Heineken, Estrella Galicia, and Therezópolis beer products in its Brazilian territories.

It operates in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Brazil, Argentina, and Uruguay.

The company was founded in 1979 and is headquartered in Mexico City, Mexico. Coca-Cola FEMSA, S.A.B. de C.V. is a subsidiary of Fomento Economico Mexicano, S.A.B. de C.V.

Latest News >

Sector Update: Consumer

Feb 18, 2025

08:55 AM EST, 02/18/2025 (MT Newswires) -- Consumer stocks were mixed pre-bell Tuesday with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.1% and the Consumer Discretionary Select Sector SPDR Fund (XLY) 0.3% higher recently. Conagra Brands ( CAG ) shares were over 5% lower after the company said it now expects fiscal 2025 adjusted earnings of about $2.35...

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

Feb 18, 2025

08:58 AM EST, 02/18/2025 (MT Newswires) -- Merus (MRUS) said Tuesday that petosemtamab in combination with pembrolizumab has received breakthrough therapy designation from the US Food and Drug Administration. The combination therapy has been designated as the first-line treatment for adult patients with recurrent or metastatic programmed death-ligand 1 positive head and neck squamous cell carcinoma, according to updated data...

Windtree Therapeutics Approves 1-for-50 Reverse Stock Split; Shares Fall Pre-Bell

Feb 18, 2025

08:56 AM EST, 02/18/2025 (MT Newswires) -- Windtree Therapeutics ( WINT ) said Tuesday that its board approved a 1-for-50 reverse stock split, to go into effect Thursday after the close of trading. The reverse split is meant to increase the share price to bring the biotech company into compliance with Nasdaq's $1.00 minimum bid price listing requirement. Shares of...

HCA Healthcare Unit to Offer Senior Notes

Feb 18, 2025

08:59 AM EST, 02/18/2025 (MT Newswires) -- HCA Healthcare Inc ( HCA ) said Tuesday its subsidiary HCA Inc. is proposing to offer senior notes, subject to market and other considerations. The actual terms of the senior notes, including maturity, interest rate, and principal amount, will depend on market conditions at the time of pricing. HCA Inc. said it plans...